Welcome to our dedicated page for Summit Therapeutics news (Ticker: SMMT), a resource for investors and traders seeking the latest updates and insights on Summit Therapeutics stock.
Summit Therapeutics Inc. develops oncology medicines led by ivonescimab, an investigational PD-1 / VEGF bispecific antibody in-licensed from Akeso. The company reports clinical and operational updates for ivonescimab programs in non-small cell lung cancer and colorectal cancer, including multiregional Phase III studies and data presentations from HARMONi trials.
Recurring Summit Therapeutics news also covers financial results, regulatory updates tied to the accepted Biologics License Application for ivonescimab in EGFR-mutated non-squamous NSCLC after tyrosine kinase inhibitor therapy, clinical trial collaborations, and equity-compensation actions under Nasdaq rules. Summit holds development and commercialization rights for ivonescimab across North America, South America, Europe, the Middle East, Africa, and Japan.
Summit Therapeutics (NASDAQ:SMMT) reported that partner Akeso received NMPA marketing authorization in China for ivonescimab plus chemotherapy as first-line treatment for patients with advanced squamous non-small cell lung cancer (NSCLC). This is the third NMPA-approved indication for an ivonescimab-containing regimen in China since its initial approval in May 2024.
The decision is based on the Phase III HARMONi-6 trial, which showed statistically significant and clinically meaningful superiority in both progression-free survival and overall survival versus tislelizumab plus chemotherapy, with an acceptable, manageable safety profile. Ivonescimab remains investigational outside China, including in Summit’s territories, where multiple Phase III trials and a US BLA review (PDUFA date November 14, 2026) are ongoing.
Summit Therapeutics (NASDAQ: SMMT) is expanding its ivonescimab program into urothelial carcinoma with the global, multi‑regional Phase II/III HARMONi‑GU1 trial. The randomized study will test ivonescimab plus enfortumab vedotin (EV) versus pembrolizumab plus EV, a widely used standard of care, as first‑line therapy for previously untreated locally advanced or metastatic urothelial carcinoma.
HARMONi‑GU1 plans to enroll about 800 patients through Phase III. Phase II will select the Phase III dose; Phase III primary endpoints are progression‑free survival and overall survival. According to Summit, global site activations are expected to begin by Q4 2026, bringing ivonescimab’s Phase III program to 16 trials across multiple tumor types, including NSCLC and CRC. Four NSCLC Phase III studies, including Summit’s HARMONi trial and three Akeso studies in China, have reported positive results. Summit’s HARMONi BLA has been accepted by the FDA with a PDUFA goal date of November 14, 2026, while ivonescimab remains investigational in Summit’s territories but was approved in China in May 2024.
Summit Therapeutics (NASDAQ: SMMT) reported second quarter 2026 results and detailed progress for its bispecific PD‑1/VEGF antibody ivonescimab. According to Summit Therapeutics, the FDA accepted its BLA for ivonescimab plus chemotherapy in EGFR‑mutated NSCLC, with a PDUFA date of November 14, 2026. An updated Phase III HARMONi OS analysis showed a hazard ratio of 0.76 for the ITT population, with the same 0.76 HR in both Asian and western subgroups.
In China’s Phase III HARMONi‑6 trial, ivonescimab plus chemotherapy achieved a statistically significant OS benefit versus a tislelizumab regimen, with an OS hazard ratio of 0.66. Enrollment in both cohorts of global Phase III HARMONi‑3 is complete. Summit ended the quarter with $690.7 million in cash and investments; Q2 2026 GAAP net loss was $215.7 million, and non‑GAAP net loss was $147.0 million.
Arcus Biosciences (NYSE: RCUS) and Summit Therapeutics (Nasdaq: SMMT) entered a clinical trial collaboration to evaluate Arcus’s HIF-2α inhibitor casdatifan (AB521) combined with Summit’s PD‑1/VEGF bispecific antibody ivonescimab in clear cell renal cell carcinoma, including first-line metastatic disease.
Arcus will sponsor and conduct a new combination cohort within its ARC‑20 platform study; Summit will supply ivonescimab. Both companies will share study costs and retain development and commercialization rights to their respective molecules. Initial data from this combination are expected by mid‑2027, adding to Arcus’s broader casdatifan program and Summit’s growing ivonescimab franchise.
Summit Therapeutics (Nasdaq: SMMT) reported updated overall survival (OS) results from the global Phase III HARMONi trial of ivonescimab plus platinum-doublet chemotherapy in EGFR‑mutated, locally advanced or metastatic non-squamous NSCLC previously treated with a third‑generation EGFR TKI. The April 2025 primary OS analysis showed a hazard ratio (HR) of 0.79 (95% CI: 0.62–1.01; p=0.057) and median OS of 16.8 vs 14.0 months for ivonescimab versus placebo, respectively. Subsequent analyses with longer follow-up, including a June 2026 data cut, yielded OS HRs of 0.78 and then 0.76 in both the intention‑to‑treat and western subgroups, aligning western outcomes with Asian patients. According to Summit, safety remained acceptable with no new signals. These data support a Biologics License Application for ivonescimab, accepted by the FDA with a PDUFA goal action date of November 14, 2026.
Summit Therapeutics (Nasdaq:SMMT) will host a conference call on Thursday, July 23, 2026, to announce its second quarter 2026 financial results and provide an update on operational progress. The call is scheduled for 4:30 p.m. EDT and will be available via live and archived webcast through the Investor Information section of the company’s website, www.smmttx.com.
Summit Therapeutics (NASDAQ: SMMT) signed an agreement to sell ridinilazole, its investigational Phase III precision antibiotic for C. difficile infection, to Toronto-based Biossil, an AI-native biopharma focused on late-stage programs in serious diseases.
Ridinilazole previously showed a higher observed Sustained Clinical Response than vancomycin in Summit’s Phase III Ri-CoDIFy trial but did not meet the prespecified primary endpoint for superiority. Earlier studies and Ri-CoDIFy indicated microbiome-sparing effects versus vancomycin. Under the agreement, Summit will receive $500,000 upfront, up to $104.5 million in regulatory and commercial milestones, and tiered royalties on net sales, while refocusing on its core oncology strategy and development of ivonescimab. Ridinilazole remains unapproved, and its safety and efficacy have not been evaluated by regulators such as the FDA.
Summit Therapeutics (Nasdaq:SMMT) has launched an underwritten public offering of $500 million in common stock, with a 30-day option for underwriters to purchase up to an additional $75 million. Completion, size, and terms of the offering remain subject to market and other conditions.
Summit plans to use net proceeds, with existing cash and cash equivalents, to fund research and development of its lead product candidate ivonescimab, and for working capital and general corporate purposes. The securities are offered under an effective Form S-3 shelf registration statement.
Summit Therapeutics (NASDAQ:SMMT) will participate in the 47th Annual Goldman Sachs Global Healthcare Conference in Miami on Monday, June 8, 2026. Management will hold a fireside chat at 10:00 AM ET, covering a corporate overview, recent progress, and development of its investigational bispecific antibody ivonescimab. A live and archived webcast will be available on the company’s website.
Summit Therapeutics (NASDAQ:SMMT) reported Phase III HARMONi-6 results for ivonescimab plus chemotherapy in 1L squamous NSCLC versus tislelizumab plus chemotherapy. Ivonescimab reduced risk of death by 34% (HR 0.66; 95% CI 0.50–0.87; p=0.0017), with 24‑month OS 64.7% vs 48.6% and median OS 27.89 vs 23.69 months.
Benefits were observed across PD-L1 subgroups. Safety was considered acceptable and consistent with prior studies, though treatment-related serious adverse events and Grade ≥3 hemorrhage were more frequent with ivonescimab. Results were presented at ASCO 2026 and simultaneously published in The Lancet.